Cargando…
吉非替尼治疗127例晚期复发非小细胞肺癌患者分类及回归树分析
BACKGROUND AND OBJECTIVE: It has been proven that gefitinib produces only 10%-20% tumor regression in heavily pretreated, unselected non-small cell lung cancer (NSCLC) patients as the second- and third-line setting. Asian, female, nonsmokers and adenocarcinoma are favorable factors; however, it is d...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999611/ https://www.ncbi.nlm.nih.gov/pubmed/21924034 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.09.04 |